Single-asset clinical development risk
Most of the company's value is tied to pemvidutide, so adverse trial results or safety issues would have an outsized impact.
- Scope
- Pemvidutide in MASH, AUD, and ALD
- Materiality
- high
Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a balanced 1:1 glucagon/GLP-1 dual receptor agonist being studied for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company is still in the development stage and has not generated product sales to date, so its business model depends on advancing clinical programs, securing financing, and potentially partnering or monetizing assets. Altimmune is headquartered in Gaithersburg, Maryland and trades on Nasdaq under the symbol ALT.
−230 187,8 %
−214 861,0 %
+105,0 %
18.55
18.55
| % | |
|---|---|
| Lead drug candidate development | 90% Clinical development of pemvidutide across liver disease and metabolic indications. |
| Pipeline expansion | 10% Evaluation of additional indications that could leverage pemvidutide's clinical profile. |
Altimmune does not sell approved commercial products, so its primary 'customers' are not end-market patients but rather...
- Clinical trial ecosystemprimary
Patients, investigators, CROs, and vendors involved in running pemvidutide studies for MASH, AUD, and ALD.
- Strategic pharmaceutical partnersprimary
Potential collaborators or acquirers that may fund, license, or commercialize pemvidutide if clinical data are compelling.
- Future prescribers and payersemerging
Healthcare providers and reimbursement decision-makers that would matter only if pemvidutide reaches approval and market launch.
Altimmune is headquartered in the United States and its principal operations are managed from Maryland...
- •Headquartered in Gaithersburg, Maryland, United States
- •Nasdaq-listed U.S. biopharma with U.S.-centered operations
- •Clinical trials may be run in the U.K. and EU
- •Foreign trial execution adds regulatory and enrollment complexity
- •Tariffs, inflation, and FX can affect trial and supply costs
Altimmune's strategy is centered on advancing pemvidutide through late-stage clinical development in MASH while also...
01
Complete and read out late-stage pemvidutide trialsshort-term
Clinical data are the main source of value because the company has no commercial revenue.
02
Expand pemvidutide into multiple liver disease indicationsmedium-term
A broader label opportunity could improve partnering leverage and commercial potential.
03
Secure external funding and strategic partnershipsshort-term
Long-duration clinical development requires capital beyond current cash resources.
Altimmune faces the classic risks of a single-asset, late clinical-stage biotech company: trial failure, delayed...
Financing and dilution risk
The company has no product revenue and must continue raising capital to fund trials and operations.
- Scope
- Equity offerings, debt financing, partnership monetization
- Materiality
- high
Regulatory and trial execution risk
Clinical timelines depend on FDA and foreign regulatory reviews, site activation, and patient enrollment.
- Scope
- U.S., U.K., EU, and other foreign trial jurisdictions
- Materiality
- high
Competitive pressure from large pharmaceutical companies
Large incumbents have greater R&D, manufacturing, and commercialization resources in overlapping therapeutic areas.
- Scope
- MASH and metabolic/liver disease markets
- Materiality
- medium
Supply-chain and macro cost inflation
Tariffs, inflation, and logistics disruptions can increase clinical and manufacturing costs.
- Scope
- Raw materials, clinical trial expenses, vendor services
- Materiality
- medium
Research and development accruals
Can materially change reported R&D expense and operating loss
Program-specific cost allocation
Affects trend analysis of pipeline spending
Short-term investment valuation and liquidity disclosure
Affects balance sheet presentation and liquidity assessment
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Aligos Therapeutics, Inc.
ALGS · Biological Products, (No Diagnostic Substances)
Prime Medicine, Inc.
PRME · Biological Products, (No Diagnostic Substances)
Evommune, Inc.
EVMN · Pharmaceutical Preparations
: 11/08/2026